GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 1,344 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,344 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $91.12, for a total value of $122,465.28. Following the completion of the transaction, the chief financial officer directly owned 7,425 shares in the company, valued at $676,566. The trade was a 15.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Monday, June 2nd, Kevin Feeley sold 370 shares of GeneDx stock. The stock was sold at an average price of $71.26, for a total value of $26,366.20.
• On Tuesday, April 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $113.09, for a total value of $43,878.92.
• On Wednesday, April 9th, Kevin Feeley sold 15,516 shares of GeneDx stock. The shares were sold at an average price of $92.18, for a total transaction of $1,430,264.88.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $91.61 on Friday. The stock has a market cap of $2.61 billion, a PE ratio of -64.97 and a beta of 2.01. GeneDx Holdings Corp. has a 52 week low of $25.32 and a 52 week high of $117.75. The company’s fifty day moving average is $73.74 and its 200 day moving average is $82.26. The company has a quick ratio of 3.07, a current ratio of 3.25 and a debt-to-equity ratio of 0.20.

GeneDx (NASDAQ:WGS) last posted its earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.17. GeneDx had a negative net margin of 11.69% and a positive return on equity of 10.17%. The company had revenue of $87.12 million during the quarter, compared to analyst estimates of $79.90 million. Research analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Analyst Ratings Changes

WGS has been the subject of several recent analyst reports. Guggenheim reiterated a “buy” rating and set a $115.00 price objective (up from $88.00) on shares of GeneDx in a research report on Monday. Wells Fargo & Company decreased their target price on GeneDx from $105.00 to $78.00 and set an “equal weight” rating for the company in a research report on Thursday, May 1st. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday, June 21st. Jefferies Financial Group upgraded GeneDx from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a report on Friday, May 9th. Finally, TD Securities decreased their price objective on shares of GeneDx from $135.00 to $110.00 and set a “buy” rating for the company in a research note on Thursday, May 1st. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $90.13.

Institutional Investors Weigh In On GeneDx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. purchased a new position in GeneDx during the fourth quarter valued at $2,645,000. Envestnet Asset Management Inc. purchased a new stake in shares of GeneDx during the 4th quarter valued at about $380,000. Prudential Financial Inc. bought a new stake in GeneDx in the 4th quarter worth approximately $7,938,000. Voya Investment Management LLC bought a new position in GeneDx in the fourth quarter valued at about $292,000. Finally, GAMMA Investing LLC boosted its holdings in shares of GeneDx by 22,194.3% in the first quarter. GAMMA Investing LLC now owns 38,792 shares of the company’s stock worth $3,436,000 after buying an additional 38,618 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.